PL

Private Life Biomed

Europe, Hamburg, Germany, Hamburg

Description

private equity

Investor Profile

Private Life Biomed has made 3 investments, with 0 in the past 12 months and 0% as lead.

Stage Focus

  • Series D (67%)
  • Series A (33%)

Country Focus

  • United States (67%)
  • Germany (33%)

Industry Focus

  • Health Care
  • Biotechnology
  • Genetics
  • Pharmaceutical
  • Health Diagnostics
  • Medical
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Private Life Biomed frequently co-invest with?

BP
North America, California, United States, San Diego
Co-Investments: 2
Mizuho Securities
Asia, Tokyo, Japan, Tokyo
Co-Investments: 2
SV
North America, Texas, United States, Austin
Co-Investments: 2
CC
North America, California, United States, San Francisco
Co-Investments: 2
BS
Europe, Ticino, Switzerland, Lugano
Co-Investments: 2
SL
North America, California, United States, Redwood City
Co-Investments: 2
CS
North America, Georgia, United States, Mcdonough
Co-Investments: 2
Maverick Ventures
North America, California, United States, San Francisco
Co-Investments: 2
Glynn Capital Management
North America, California, United States, Menlo Park
Co-Investments: 2
Brookside Capital
North America, California, United States, San Francisco
Co-Investments: 2

What are some of recent deals done by Private Life Biomed?

EyeSense AG

Großostheim, Bayern, Germany

EyeSense AG develops ophthalmic diagnostic systems.

Health CareHealth DiagnosticsMedical
Series AFeb 10, 2006
Amount Raised: $8,208,354
Perlegen Sciences

Mountain View, California, United States

Perlegen Sciences develops genetic variations providing physicians with information to improve the clinical process and treatment outcomes.

BiotechnologyGeneticsHealth CarePharmaceutical
Series DJan 6, 2006
Amount Raised: $50,000,000
Perlegen Sciences

Mountain View, California, United States

Perlegen Sciences develops genetic variations providing physicians with information to improve the clinical process and treatment outcomes.

BiotechnologyGeneticsHealth CarePharmaceutical
Series DFeb 28, 2005
Amount Raised: $74,000,000